In processes such as apoptosis and necrosis, how cells choose to die remains a mystery
Reveal Brighter, Healthier-Looking Skin
Eli Lilly and Company reports P-III (TRIUMPH-1) trial results for triple agonist retatrutide, demonstrating up to 28.3% mean weight loss at 80 weeks and 30.3% at 104 weeks in adults with obesity or overweight without diabetes Subscribe to our weekly newsletter and never miss a beat: #elililly #retatrutide #triumph1 #obesity #overweight #piii #diabetes #weightloss #clinicaltrial PharmaShots Post Eli Lilly and Company reports P-III (TRIUMPH-1) trial results for triple agonist retatrutide, demonstrating up to 28.3% mean weight loss at 80 weeks and 30.3% at 104 weeks in adults with obesity or overweight without diabetes Subscribe to our weekly newsletter and never miss a beat: #elililly #retatrutide #triumph1 #obesity #overweight #piii #diabetes #weightloss #clinicaltrial More from this author PharmaShots Weekly | Jul 27, 2026 Edition CXO Talks Podcast | Building Smarter Biotech: Venkat Nelabhotla, CEO of Vyome Holdings, on Driving Innovation Across the USIndia Corridor Gona Aziz at HLTH Europe 2026 on the Convergence of AI & 5T MRI: United Imagings Strategy for Advancing Precision Healthcare
Full therapeutic doses are a separate and more promising story, now in trials for depression and, as covered above, in an early test in Parkinsons
All strains were maintained on a C57BL/6 background
Our study preliminarily predicted that SIRT1 may be a core target of GHK in the treatment of UC by utilizing network pharmacology and molecular docking
